HBM Holdings Ltd

02142

Company Profile

  • Business description

    HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9378, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others. The majority of the revenue for the firm is generated from the United States.

  • Contact

    218 Xinghu Street
    Suite 202, Building A3, Suzhou Industrial Park
    Suzhou215123
    CHN

    T: +86 51265790025

    https://www.harbourbiomed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    183

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,787.9044.300.51%
CAC 407,691.55134.241.78%
DAX 4024,033.22383.921.62%
Dow JONES (US)43,819.27432.431.00%
FTSE 1008,798.9163.310.72%
HKSE24,185.1599.00-0.41%
NASDAQ20,273.46105.550.52%
Nikkei 22540,755.57604.781.51%
NZX 50 Index12,573.999.60-0.08%
S&P 5006,173.0732.050.52%
S&P/ASX 2008,560.1045.900.54%
SSE Composite Index3,431.186.950.20%

Market Movers